Literature DB >> 25400453

Mechanism of gastrointestinal abnormal motor activity induced by cisplatin in conscious dogs.

Hiroyuki Ando1, Erito Mochiki1, Tetsuro Ohno1, Mitsuhiro Yanai1, Yoshitaka Toyomasu1, Kyoichi Ogata1, Yuichi Tabe1, Ryuusuke Aihara1, Toshihiro Nakabayashi1, Takayuki Asao1, Hiroyuki Kuwano1.   

Abstract

AIM: To investigate whether 5-hydroxytryptamine (serotonin; 5-HT) is involved in mediating abnormal motor activity in dogs after cisplatin administration.
METHODS: After the dogs had been given a 2-wk recovery period, all of them were administered cisplatin, and the motor activity was recorded using strain gauge force transducers. Blood and intestinal fluid samples were collected to measure 5-HT for 24 h. To determine whether 5-HT in plasma or that in intestinal fluids is more closely related to abnormal motor activity we injected 5-HT into the bloodstream and the intestinal tract of the dogs.
RESULTS: Cisplatin given intravenously produced abnormal motor activity that lasted up to 5 h. From 3 to 4 h after cisplatin administration, normal intact dogs exhibited retropropagation of motor activity accompanied by emesis. The concentration of 5-HT in plasma reached the peak at 4 h, and that in intestinal fluids reached the peak at 3 h. In normal intact dogs with resection of the vagus nerve that were administered kytril, cisplatin given intravenously did not produce abnormal motor activity. Intestinal serotonin administration did not produce abnormal motor activity, but intravenous serotonin administration did.
CONCLUSION: After the intravenous administration of cisplatin, abnormal motor activity was produced in the involved vagus nerve and in the involved serotonergic neurons via another pathway. This study was the first to determine the relationship between 5-HT and emesis-induced motor activity.

Entities:  

Keywords:  5-hydroxytryptamine; Abnormal motor activity; Cisplatin; Dog; Emesis

Mesh:

Substances:

Year:  2014        PMID: 25400453      PMCID: PMC4229534          DOI: 10.3748/wjg.v20.i42.15691

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis.

Authors:  B Costall; A M Domeney; R J Naylor; F D Tattersall
Journal:  Neuropharmacology       Date:  1986-08       Impact factor: 5.250

2.  Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.

Authors:  P B Bradley; G Engel; W Feniuk; J R Fozard; P P Humphrey; D N Middlemiss; E J Mylecharane; B P Richardson; P R Saxena
Journal:  Neuropharmacology       Date:  1986-06       Impact factor: 5.250

3.  Effect of cisplatin on myoelectric activity of the stomach and small intestine in dogs.

Authors:  R D Chey; K Y Lee; R Asbury; W Y Chey
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

4.  5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret.

Authors:  G A Higgins; G J Kilpatrick; K T Bunce; B J Jones; M B Tyers
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

5.  DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog.

Authors:  N Yoshida; H Omoya; T Ito
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

Review 6.  Serotonin: its role and receptors in enteric neurotransmission.

Authors:  M D Gershon
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

7.  Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs.

Authors:  H Fukui; M Yamamoto; S Sato
Journal:  Jpn J Pharmacol       Date:  1992-06

8.  Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs.

Authors:  B Costall; A M Domeney; R J Naylor; F D Tattersall
Journal:  Neuropharmacology       Date:  1987-09       Impact factor: 5.250

9.  BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.

Authors:  J A Gylys; R N Wright; W D Nicolosi; J P Buyniski; R R Crenshaw
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

10.  The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.

Authors:  J Bermudez; E A Boyle; W D Miner; G J Sanger
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more
  2 in total

1.  Gastric myoelectric activity during cisplatin-induced acute and delayed emesis reveals a temporal impairment of slow waves in ferrets: effects not reversed by the GLP-1 receptor antagonist, exendin (9-39).

Authors:  Zengbing Lu; Man P Ngan; Ge Lin; David T W Yew; Xiaodan Fan; Paul L R Andrews; John A Rudd
Journal:  Oncotarget       Date:  2017-10-16

2.  Thyroid hormone activated upper gastrointestinal motility without mediating gastrointestinal hormones in conscious dogs.

Authors:  Nobuhiro Nakazawa; Makoto Sohda; Kyoichi Ogata; Seded Baatar; Yasunari Ubukata; Kengo Kuriyama; Keigo Hara; Masaki Suzuki; Toru Yanoma; Akiharu Kimura; Norimichi Kogure; Akihiko Sano; Makoto Sakai; Takehiko Yokobori; Atsushi Oue; Erito Mochiki; Hiroyuki Kuwano; Ken Shirabe; Noriyuki Koibuchi; Hiroshi Saeki
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.